Rituximab reduces the incidence of acute graft-versus-host disease

Blood

Volumn 113, Issue 13, 2009, Pages 3130-3131

  Behre, Gerhard ^a   Christopeit, Maximilian ^a   Schütte, Vincent ^a   Theurich, Sebastian ^a   Weber, Thomas ^a   Grothe, Wilfried ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; BODY WEIGHT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INFORMED CONSENT; KARNOFSKY PERFORMANCE STATUS; LETTER; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 63849167930     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-200527     Document Type: Letter

References (9)

1. Hauser SL, Waubant E, Arnold L, et al. B-cell depletion with rituximab in re-lapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676-688.
2. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350:2572-2581.
3. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology(Oxford). 2005;44:176-182. 4. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
4. Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006;38:203-209.
5. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992.
6. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005; 105:2227-2234.
7. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
8. Iori AP, Torelli GF, De Propris MS, et al. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation. 2008;85:386-390.
9. Glass B, Hasenkamp J, Görlitz A, et al. Rituximab for graft-versus-host-dis-ease-prophylaxis after allogeneic stem cell transplantation given as treatment of high risk relapse of aggressive lymphoma: results of a randomized phase II study [abstract 1974]. Blood. 2008;112:689.